In August 2013, a federal judge preliminarily approved a $23 million settlement to a class-action lawsuit filed against Merck Sharp & Dohme Corp. for allegedly falsely advertising that Vioxx had greater benefits than the generic versions when these benefits had not been established. According to the settlement terms, class members may receive a cash award of up to $75 with proof of purchase. (In re: Vioxx Products Liability Litigation, MDL No. 1657, E. D. LA.).


The Latest


Show More